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Abstract One person on three will receive a diagnostic of
cancer during his life. About one third of them will die of
the disease. In most cases, death will result from the
formation of distal secondary sites called metastases.
Several events that lead to cancer are under genetic control.
In particular, cancer initiation is tightly associated with
specific mutations that affect proto-oncogenes and tumour
suppressor genes. These mutations lead to unrestrained
growth of the primary neoplasm and a propensity to detach
and to progress through the subsequent steps of metastatic
dissemination. This process depends tightly on the sur-
rounding microenvironment. In fact, several studies support
the point that tumour development relies on a continuous
cross-talk between cancer cells and their cellular and
extracellular microenvironments. This signaling cross-talk
is mediated by transmembrane receptors expressed on
cancer cells and stromal cells. The aim of this manuscript
is to review how the cancer microenvironment influences
the journey of a metastatic cell taking liver invasion by
colorectal cancer cells as a model.
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Introduction
Carcinogenesis is a multistep process that results from
genetic alterations that underlie the transformation of
normal cells into malignant derivatives. In fact, the genome
of tumour cells is altered at several sites as a result of point
mutations or changes in chromosome integrity. It is now
accepted that cancer arises from a succession of genetic
alterations that confer growth advantages leading to the
progressive conversion of normal cells into cancer cells [1].
The genetic modifications that contribute to cancer initia-
tion and progression are regrouped within six phenotypic
traits that constitute the essential hallmarks of cancer. These
have been described in detail in a didactic review by
Hanahan and Weinberg and are summarized in Fig. 1 [1].
Firstly, cancer cell have acquired self-sufficiency of growth
through mutations that activate proto-oncogenes allowing
cancer cells to generate their own growth signals such as
secretion of transforming growth factor-α (TGFα) or
platelet-derived growth factor (PDGF). Secondly, cancer
cells are characterized by their insensitivity to antigrowth
signals, in part through disruption of the Rb pathway.
Thirdly, cancer cells have gained the capability to escape
apoptosis through mutations that inactivate tumour sup-
pressor genes such as p53 or PTEN, or through activation
of survival pathways involving insulin-like growth factor-1/
2 (IGF1/2) or interleukin-3 (IL-3). Fourthly, cancer cells
have lost the cell-autonomous program that limits their
multiplication. This results mainly from turning on of
telomerase, an enzyme that maintains the telomeres at the
end of chromosomes, thereby impairing senescence and
death. Fifthly, the growing neoplasm becomes capable to
sustain its oxygen and nutritive supplies by promoting
angiogenesis. This neovascularization process is turned on
by the expression of pro-angiogenic agents such as vascular
endothelial growth factor (VEGF) produced by cancer cells
or by the repression of anti-angiogenic processes such as a
fall in thrombospondin levels. Sixthly, cells from the
primary neoplasm detach from this site to invade adjacent
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tissues and travel to distant sites that they will colonize to
form metastases. Recent studies have indicated that during
the acquisition of these inherent hallmarks, the cancer cells
need to interact synergistically with their surrounding
microenvironment to form a neoplasm and to progress
further to colonize distant organs. This review will focus on
the major cancer cell-microenvironment interactions that
pave the journey of a metastatic cell from the primary site
to the metastatic site, taking the invasion of the liver by
colorectal cancer cells as a model.
Interaction of the Primary Neoplasm
with its Microenvironment
Colorectal cancer arises mostly from dysplastic adenoma-
tous polyps. As with other types of cancers, it involves a
multistep process characterized by the inactivation of a
variety of genes that suppress tumours (e.g.: APC, DCC,
p53) and repair DNA (e.g.:hMSH2, hMSLH1) and the
simultaneous activation of proto-oncogenes (e.g.: K-ras, N-
Ras and c-Myc). This confers a selective growth advantage
to colonic epithelial cells and triggers the transformation of
the normal epithelium into pre-cancerous adenomatous
polyps and subsequently leads to local invasion and
metastasis. There are several distinct neoplastic syndromes
in which individuals display a marked predisposition to the
development of colorectal cancer. In particular, genetic
lesions in the familial form of adenomatous polyposis
(FAP) and hereditary non-polyposis colorectal cancer
(HNPC) are now well delineated and their study has
contributed enormously to our understanding of the
molecular pathology of sporadic colorectal cancer [2].
Beyond the intrinsic genetic alterations that affect the colon
cancer cells, a dynamic interaction occurs between cancer
cells and the host stromal microenvironment to support
cancerous growth and dissemination [3, 4]. The stroma is
constituted mainly of cellular elements such as fibroblasts
and non-cellular elements such as the extracellular matrix
(ECM). These stromal elements act in a synergistic cross-
talk with cancer cells from the primary sites to sustain
cancer growth and metastasis. The importance of the stroma
in cancer is highlighted by histological observations
indicating that some types of neoplasms such as pancreatic
cancer are composed mostly of stromal cells [5, 6]. We will
first review the influence played by the stroma on the
development of the primary neoplasm and thereafter on the
formation of metastases.
Influence of Stromal Cells on the Primary Neoplasm Cancer
cells of the primary neoplasm constitute a histological
lesion that is embedded in the stromal microenvironment of
a given tissue. The tumour stroma plays an essential role in
the development of colorectal cancer and is referred to as a
“reactive stroma” [7]. This reactive stroma is associated
with an increased number of fibroblasts, enhanced capillary
density and deposition of a new ECM rich in type-
1-collagen and fibrin. Macrophages are also recruited in
the reactive stroma in response to the healing process
generated by the tumour. There is evidence indicating that
the primary neoplasm and the reactive stroma communicate
in a reciprocal way via the basement membrane [7].
Moreover, several studies show that the reactive stroma
influences the initiation and promotion of cancer by
secreting cytokines and growth factors or by expressing
their receptors (Fig. 2). For example, stromal cells within
colon carcinoma express high level of PDGF receptor
(PDGFR). In turn, this has a marked impact in colon cancer
progression since chemical inhibition of PDGFR signaling
in the stromal cells inhibits cancer progression [8]. On the
other hand, several studies indicate that fibroblasts within a
tumour harbor mutations that activate them into myofibro-
blasts or cancer associated fibroblasts (CAFs). These
genetically altered fibroblasts may directly be involved in
cancer initiation as demonstrated in mouse models. For
example, when immortalized prostate epithelial cells are
grafted in mice together with normal fibroblasts or CAFs
taken from the primary site, intraepithelial neoplasia of the
prostate emerge only in the presence of CAFs [9]. This
clearly indicates that CAFs have the potential to initiate
tumour formation. Along these lines, CAFs produce
cytokines such as TGFβ that activate cancer cells and
Fig. 1 The hallmarks of cancer cells. Cancer cells from most human
cancers share six acquired traits that collectively dictate malignant
growth: (a) self-sufficiency with respect to growth signals, (b)
insensitivity to growth-inhibitory signals, (c) evasion of programmed
cell death, (d) limitless replicative potential, (e) sustained angiogen-
esis, and (f) tissue invasion and metastasis. All these traits contribute
to growth, detachment and invading potential of cancer cells (adapted
from [1])
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trigger their detachment from the primary neoplasm.
Interestingly, a recent study showed that TGFβ also leads
to the transformation of lung endothelial cells into CAFs,
which favors progression of lung cancer in a mouse
model. Overall, this study indicates that endothelial cells
contribute to expand the pool of CAFs that synergize
with cancer cells to favor their progression [10]. This
important study further highlights the intricate signaling
network that exists between a tumour and its environment.
Macrophages are another important type of cells
recruited to the primary neoplasm. These tumour-associated
macrophages (TAMs) can constitute a large proportion of
the tumour mass [11]. Incidentally, their recruitment to the
tumours is a response to cancer-associated inflammation
and it may explain why some cancers respond to anti-
inflammatory agents [12, 13]. The importance of these
TAMs in cancer is supported by the fact that their presence
within a tumour correlates with a poor prognosis. As a
corollary, removal of macrophages in mice (via a homozy-
gous null mutation of the genes encoding macrophage
growth factor, colony stimulating factor-1) reduces the rate
of tumour progression and impairs metastasis in a mouse
model of breast cancer [14]. In an excellent review,
Condeelis and Pollard proposed six extrinsic traits by
which macrophages enhance tumour incidence, progression
and metastasis. These are chronic inflammation, matrix
remodeling, tumour cell invasion, intravasation, angiogen-
esis and seeding at distant sites [15]. In the case of colon
cancer, it seems that TAMs favor metastasis by secreting
VEGF, thereby promoting angiogenesis at the primary site
[16]. Intriguingly, a recent study shows that TAMs promote
removal of apoptotic colon cancer cells that express the
sulfoglycolipids SM4s. During the process, the phenotype
of TAMs is modified, as it is associated with an increased
expression of TGF-β1 and secretion of IL-6. This pheno-
typic modification may putatively contribute to further
activate the angiogenic process [17].
Interestingly, the recruitment of macrophages and other
immune cells to a tumour contributes to develop adaptive
immune response against this tumour. Along these lines,
certain subsets of lymphocytes within a tumour are
associated with a favorable prognostic. In particular, the
presence of intra-tumoural T cells correlates with a better
clinical outcome in advanced colorectal carcinoma [18, 19].
Tumours also develop mechanisms that allow evading
immunosurveillance [20]. Tumour-infiltrating macrophages
may generate arginine metabolites that lead to T-cell death
[20]. More insidiously, tumour cells or their microenviron-
ment can produce molecules that kill effector T cells. For
example, colon cancer cells show an increased production
of Fas ligand that binds to its receptor on immune cells to
trigger their apoptosis and decrease immunosurveillance
[21]. Another mechanism developed by cancer cells to
escape the immune system is to increase the expression of
carbohydrates at their surface. This masks surface antigens
on the cancer cells, thereby impeding their recognition by
immune cells. In this context, galectin-1 expression by head
and neck cancer cells negatively correlates with patient
survival [22]. Moreover, it is now apparent that in tumour
draining lymph nodes of advanced cancers, dendritic cells
are actively immunosuppressive. These dendritic cells do
not activate T cells but rather induce tolerance to tumour
antigens [23].
Influence of the Extracellular Matrix on the Primary
Neoplasm Most mammalian cells are in contact with an
ECM whose composition and structure vary with develop-
ment and diseases such as cancer as well as with cell types
and their location. The ECM is composed of five classes of
macromolecules (collagens, laminins, fibronectins, proteo-
glycans and hyaluronans). Each class of macromolecules
exists as various isoforms depending on the cell type within
the ECM. By binding to integrins at the cell surface, the
ECM provides mechanical and physicochemical support for
cells. It also provides pathways for cell migration and
sequesters growth factors that influence cellular behaviour.
The basement membrane (BM), a specialized sheet pro-
duced through cooperation of epithelial and stromal cells, is
a particular type of ECM with a significant role in cancer. It
is a dense meshwork of ECM molecules such as Type IV
collagen, laminins, Type VII collagen, and heparan sulfate
proteoglycans. Type IV collagen is a major structural
component of BMs that forms a network enabling the
binding of other BM components. Inappropriate synthesis
or degradation of any ECM molecules alters cell physiol-
Fig. 2 Interaction of cancer cells with the microenvironment. Beyond
genetic alterations that affect cancer cells, a dynamic interaction
occurs between cancer cells and the host stromal microenvironment to
support cancerous growth and dissemination. The stroma is constitut-
ed mainly of cellular elements such as fibroblasts and immune cells,
and non-cellular elements such as ECM. These stromal elements act in
a synergistic cross-talk with the cancer cells from the primary sites to
sustain cancer growth and metastasis. For example, cancer-associated
macrophages and fibroblasts influence cancer initiation/promotion by
secreting cytokines, growth factors and chemokines
Cancer microenvironment in metastasis 71
ogy and causes disease. Accordingly, a loss of BM
components due to degradation by proteolytic enzymes and/
or a lack of biosynthesis are correlated with tumour
progression. For example, Type VII collagen is lost early in
the development of malignant melanoma [24], breast cancers
[25], and prostate carcinomas [26]. Similarly, laminin-5 is
commonly lost in colon carcinomas but not in pre-malignant
tumours. On the other hand, de novo synthesis and/or
deposition of BM components are associated with different
types of tumours, which suggests an active role for BM
molecules in tumour invasion. In gastric, liver, and pancre-
atic carcinomas, laminins are produced and deposited at the
invasive front of the tumour clusters. The expression of
laminin-1 in gastric carcinoma is a risk factor for liver
metastasis. Moreover, in human gastric and pancreatic
carcinomas, laminin-5 is expressed by invasive malignant
cells, and is considered as a marker of invasiveness [27–30].
These modifications of the BM occur simultaneously to
changes in transmembrane adhesive receptors expressed by
tumour cells in response to the “new” ECM ligands. In this
sense, the best-characterized example is the “switch” of
function of the α6β4 integrin. The usual role of this integrin
is to provide stable adhesion of epithelial cells to BM.
However, this integrin has been identified as a tumour
antigen also designated as TSP-180 or A9 [31, 32].
Furthermore, increased expression of α6β4 and changes in
its distribution correlate with increased aggressiveness of
tumours and poor prognosis [33, 34]. In colon carcinoma,
the α6β4 integrin promotes cell migration on laminin-1,
since it induces and stabilizes actin-containing motility
structures, instead of being associated with hemidesmosomes
to support stable adhesive structures [35].
Metabolism of ECM molecules is an important aspect of
tissue homeostasis and determines how cells respond to
acute and chronic stresses. Various types of proteinases
participate in ECM turnover, but matrix metalloproteinases
(MMPs) are the principal ECM-degrading enzymes. These
enzymes have a central role in cancer progression given
that ECM degradation products can influence stroma–
cancer cell interactions. In particular, metastatic colon cancer
cells are able to induce the expression and/or secretion of
MMP-2 and MMP-9 in stromal cells, either via direct contact
or via a paracrine regulation [36]. Because of the multi-
functionality of MMPs, it is conceivable that they influence
several stages of cancer development.
Epithelial–Mesenchymal Transition Cancer cell detach-
ment from the primary site is one of the key initial events
required for metastasis. This is tightly associated with
epithelial–mesenchymal transition (EMT), a morphogenetic
process in which epithelial cells loose their characteristics
and gain mesenchymal properties during embryogenesis
[37] (Fig. 3). There is now accumulating evidence
indicating that carcinoma cells usurp normal developmental
EMT to detach from the primary neoplasm and migrate to
distant sites. In this context, histochemical studies reveal
that adenocarcinoma is accompanied by the release of
single cells through EMT [38]. In particular, it appears that
EMT is an integral component of colorectal cancer
progression [39, 40]. One of the major elements that
characterize EMT of carcinoma cells is the loss of E-
cadherin-mediated cell–cell adhesion [41]. This latter event
results from mutations in the E-cadherin gene, proteolytic
degradation of E-cadherin, IGF1-mediated internalization
of E-cadherin and disruption of the function of E-cadherin
involving β-catenin [41]. Loss of E-cadherin further results
from a decrease in its expression that is subsequent to
promoter hypermethylation and activation of transcriptional
repressors such as Snail and FOXC2 [42, 43]. In colon
cancer cells, deregulation of E-cadherin and EMT is
associated with a peripheral accumulation of Src and
phospho-myosin and with an increased expression of the
guanine nucleotide exchange factor TIAM 1 [44, 45].
Moreover, the level of RhoC varies widely in colon cancer
cells and an elevated RhoC expression correlates with a
poor prognostic and with an aberrant expression and
localization of E-cadherin [46]. Interestingly, in melanoma,
breast cancer and prostate cancer, the disruption of the E-
cadherin-mediated cancer cell adhesion is associated with
the so-called cadherin-switch in which the E-cadherin loss
is accompanied by de novo expression of mesenchymal
cadherin, such as N-cadherin. This shift is important since
the loss of E-cadherin by cancer cells is associated with
their inability to adhere with themselves and with normal
Fig. 3 The epithelial–mesenchymal transition. Epithelial-to-Mesenchymal
Transition (EMT) is a morphogenetic process in which epithelial
cells loose their characteristics and gain mesenchymal properties
during embryogenesis and during progression of cancer. Carcinoma
cells acquire a mesenchymal-like state in order to facilitate their
migration and invasion. The EMT process is induced and regulated
by effectors such as growth factors (TGFβ, PDGF, EGF), cytokines
(Il-8) and ECMcomponents. It is characterized by loss of epithelial markers
such as E-cadherin and cytokeratins and gain of mesenchymal markers
such as N-cadherin and vimentin
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epithelial cells. Furthermore, by up-regulating the expres-
sion of N-cadherin, cancer cells will interact with stromal
cells, thereby changing their location and favoring the
invasion of the surrounding stroma. Moreover, N-cadherin
confers motility and migration to cancer cells [47]. Hence,
the cadherin switch is an important component of the EMT
that characterizes the early step of cancer progression
toward an invasive and metastatic phenotype (Fig. 3).
The Tumour Microenvironment in Epithelial–Mesenchymal
Transition Signaling The tumour microenvironment is a
potent factor that may facilitate and even initiate EMT. In
this regard, several arguments support the concept that
cancer EMT is importantly regulated by the surrounding
stroma via the activation of the same signaling pathways as
those regulating EMT during embryogenesis. Among
others, embryonic and cancer EMTs are characterized by
fluctuating levels of TGFβ, EGF and PDGF [3]. Notably,
TGFβ signaling is associated with the induction and
maintenance of EMT and its effect may be mediated
through autocrine and paracrine pathways [48]. For
example, TGFβ plays a crucial role in EMT of colon
cancer cells and it has been proposed that its role is
triggered by TNFα produced by infiltrating macrophages
[49, 50]. Typically, the binding of TGFβ with serine–
threonine kinase receptors TGFβR1/TGFβR2 triggers the
phosphorylation of the Smad2/Smad3 dimers that dissociate
from the receptors to interact with Smad4 before entering
the nucleus to regulate transcriptional modulation of EMT.
In particular, in kidney tubular epithelia and NMuMG
breast epithelial cells, TGFβ-induced EMT is dependent on
the down-regulation of E-cadherin via Smad3 [51]. More-
over, the high mobility group A2 (HMGA2) gene is induced
by the TGFβ–Smad pathway, which is necessary and
sufficient for TGFβ-induced EMT. HMGA2 is a nuclear
factor that links TGFβ signaling with the EMT-inducing
transcription factors Snail1, Snail2 and Twist [52]. Signal-
ing pathways that mediate the activity of β-catenin and
LEF may also cooperate with TGFβ/Smads to form new
transcriptional complexes inducing EMT [3]. For example,
PDGF and PDGFR signaling is essential for TGFβ-induced
EMT in mammary epithelial cells. It is possible that these
pathways interact at the transcriptional level. Along these
lines, TGFβ/Smads may interact with the PDGFR-depen-
dent phosphorylation of nuclear p68 RNA helicase to
trigger nuclear translocation of β-catenin via a Wnt-
independent pathway [53]. Several other signaling path-
ways activated by TGFβ are also involved in modulating
EMT. In NMuMG mouse mammary epithelial cells, TGFβ,
produced via an autocrine pathway, induces EMT in
conjunction with integrin β1, upstream of RhoA and the
p38 MAP kinase [54, 55]. Interestingly, it has been
proposed that the propensity of colon cancer to undergo
EMT relies on a synergistic cooperativity between contin-
uous TGFβ signaling and an activated Ras pathway [39,
56]. In mice, Ras-transformed EpH4 cells progressively
acquire a mesenchymal phenotype in association with an
autocrine production of TGFβ [3]. On the other hand, Ras-
transformed hepatocytes and MDCK cells undergo TGFβ-
induced EMT in contrast to their parental counterpart and
this effect transits through both ERK and PI3 kinase
pathways [57]. The precise events that modulate TGFβ-
mediated EMT via these pathways are unclear. However,
it is likely that they are associated with cytoskeletal
remodeling and increased cell motility. In this context, the
expression of integrin α6β4 as a consequence of the EMT
enables motile and invasive colorectal cancer cells to
interact with interstitial matrices and to sustain activation
of TGFβ [39].
Overall, a lot of observations converge on the fact (1)
that cancer EMT “highjacks” the same signaling pathways
as those leading to embryonic EMT, and (2) that tumour
microenvironment may act as an initiator of these signaling
cascades.
Angiogenesis Tumour growth and progression are both
dependent on angiogenesis to provide cancer cells with
oxygen and nutriments required for their growth. In fact,
cancer cells cannot grow when they are located at a
distance greater than 110 μm from a blood vessel. At a
later stage during the process, angiogenesis is further
involved as an important step of metastasis, given that the
cancer cells that detach from the primary site will use the
new vessels as a road to reach and colonize new sites.
Accordingly, cancer cells begin to promote angiogenesis
early in tumourigenesis in order to sustain their growth. The
process of angiogenesis is regulated by a tight balance
between pro- and anti-angiogenic agents. Typically, the
“angiogenic switch” is initiated by tumour-associated
hypoxic conditions, which contributes to activate the
transcription of hypoxia-inducible factor-1 (HIF-1). In turn,
HIF-1 promotes the expression of several angiogenic
factors by the cancer cells including VEGF, basic fibroblast
growth factor (bFGF) and placenta-like growth factor
(PLGF) [58]. Interestingly, there is accumulating evidence
indicating that the expression of these angiogenic agents by
cancer cells is also increased through HIF-1-independent
pathways [59]. In this context, tumour angiogenesis is
preserved in HIF-1-deficient xenografts [60]. It seems that
oncogenic ras and the intracellular levels of calcium play a
key role in regulating angiogenic gene expression in
response to hypoxia [59]. Once they are expressed, the
angiogenic growth factors interact with their respective
receptors at the surface of endothelial cells activating
the angiogenic program. In particular, VEGF binds to
VEGFR2, which triggers signaling cascades involving
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eNOS, PI3 kinase, p38 and ERK MAP kinases and leading
to the induction of vasodilatation, endothelial cell migra-
tion/proliferation and vessel assembly [61]. Fibroblasts in
or near the tumour bed also produce pro-angiogenic factors,
and tumours recruit progenitor endothelial cells from bone
marrow. The angiogenic switch also involves down-
regulation of angiogenesis suppressor proteins, such as
thrombospondin [62]. We will not further review the
mechanisms of angiogenesis, as the topic has been covered
in recent reviews [61, 63, 64].
Angiogenesis is importantly involved in the growth and
dissemination of colorectal cancer, and the level of
angiogenesis is a predictor of survival in patients with this
disease [65]. Along these lines, a color doppler vascularity
index (ratio of colored pixels/total pixels per tumour
section) predicts distant metastasis and survival in colon
cancer patients. More precisely, patients who have a
doppler vascularity index at the primary site greater than
15% have a poorer overall survival than the patients with an
index <15% [66]. As a corollary, the doppler hepatic
perfusion index (ratio of hepatic arterial flow to total liver
flow) is increased even in patients with occult micro-
metastases and is predictive of subsequent hepatic relapse
[67]. Similarly, the correlation existing between angiogen-
esis of the primary colon cancer site and distal hepatic sites
is supported by several imaging approaches including
dynamic contrast-enhanced magnetic resonance imaging
and contrast-enhanced computed tomography [65]. The
importance of angiogenesis in colon cancer metastasis to
the liver is further highlighted by the finding that anti-
angiogenic agents such as the anti-VEGF-directed antibody
bevacizumab in combination with standard chemotherapy
offers stimulating promises in blocking the metastatic
process and prolonging patient survival [68].
Lymphangiogenesis In solid cancers including colorectal
cancer, the status of the lymph node is the most important
prognostic indicator for the clinical outcome of patients
[69–71]. However, the mechanistic basis underlying the
role played by the lymphatic system in metastasis remained
rather elusive until the pioneered work of Kari Alitalo’s
group who reported the existence of lymphangiogenesis
and showed that the process is used by cancer cells to
disseminate [72]. VEGF-C is the main regulator of
lymphangiogenesis, and its levels correlate with lymph
node metastases. The VEGF-C lymphangiogenic effect is
mediated through its binding to VEGFR-3 present on
lymphatic endothelial cells. VEGF-D also binds to this
receptor and contributes to lymphangiogenesis. The activa-
tion of this receptor in association with β1 integrin sub-unit
initiates different signaling pathways in the lymphatic
endothelial cells, including ERK and JNK MAP kinases,
Pyk2, NF-κB and AKT, that govern proliferation, survival
and sprouting [73]. As for blood vessel angiogenesis,
several other growth factors participate to lymphangio-
genesis. In particular, angiopoietin-1, by binding to its
receptor Tie2, promotes lymphatic vessel sprouting, hyper-
plasia and growth in experimental animal models [74]. At
present, it is not clear how lymphangiogenesis is induced
but it is likely that it follows similar steps as blood vessel
angiogenesis. Moreover, lymphangiogenesis may be initi-
ated by the incorporation of circulating endothelial progen-
itors (CEPs) into existing lymphatic vessels. CEPs are a
subpopulation of circulating endothelial cells (CECs)
derived from the bone marrow [71]. These CEPs are more
abundant in the circulation during pathological conditions
including cancer. Interestingly, a subset of CD34+ cells
co-express VEGFR-3 and CD133 and may represent a
subpopulation of lymphatic endothelial progenitors that
may migrate from the circulation and integrate into ex-
panding tumour-related lymphatic vessels [75]. Other
studies also show that peri-tumoural lymphangiogenesis
occurs without incorporation of donor-derived CEPs. In this
context, tumour lymphangiogenesis in a mouse xenograft
model can occur by sprouting from pre-existing local
lymphatic networks without contribution of CEP [76]. An
alternative contribution to tumour lymphangiogenesis is the
transdifferentiation of other cell types especially macro-
phages and host stromal cells into lymphatic endothelial
cells [77, 78].
Lymphangiogenesis is present in colorectal cancer and
the lymphatic vessel density of the tumour correlates with
depth of invasion and metastasis not only to regional lymph
nodes but also to the liver. The reason for the close
correlation between hepatic and lymph node metastasis of
colorectal cancer is still unclear. One possibility relies on
the fact that colorectal cancer cells express the CXCR5
chemokine receptor and that both lymph endothelial cells
and the liver express its ligand BCA-1/CXCL13 [79].
Hence, it is possible that cancer cells may be directed via
lymphangiogenesis to both lymph nodes and liver, which
would explain the correlation between lymph node and
liver metastasis of colon cancer. On the other hand, lymph
node metastases are found at the site of lymph node
drainage of the liver namely, celiac, portal and mediastinal
lymph nodes. This further raises the possibility that these
lymph node metastases are derived from the liver metasta-
ses during a process of colon cancer re-metastasis [80].
Here again, this finding could explain the correlation
between lymph node and liver metastasis of colorectal
cancer.
Obviously, tumour blood vessel angiogenesis and lym-
phangiogenesis are among the best examples of the
insidious cross-talk that occurs between colon cancer cells
and their surrounding stroma in tumour development and
dissemination.
74 S. Gout, J. Huot
Intravasation of Cancer Cells
Following their detachment from the primary neoplasm,
cancer cells enter or intravasate into the existing or newly-
formed blood or lymphatic vessels to disseminate. The
process of intravasation is not very well understood in the
case of colon cancer. Several molecular steps involving
matrix metalloproteinases and interaction between cancer
cells and endothelial adhesion molecules have been
described. For example, studies in patients with familial
adenomatous polyposis, indicate that urokinase plasmino-
gen activator (u-PA) levels increase during the normal
epithelia transition to dysplastic lesions, thus implicating
u-PA in the early stages of tumour development [81, 82]. In
fact, the u-PA system plays a determinant role in the
intravasation of colorectal cancers [83]. Following its
binding to receptor (u-PAR), u-PA activates plasminogen
and other proteases such as matrix metalloproteinases-2
(MMP-2) and MMP-9. In turn, this contributes to break-
down the ECM, a step that favors intravasation. A recent
study has shown that u-PAR gene expression is induced
downstream of Src-mediated activation of the AP-1
promoter and by c-Jun phosphorylation at Ser73 and
Ser63. Src activity increases during the transition from
benign colonic polyps to primary colon cancers and to
colon cancer metastases [84]. In addition, Src activity is
associated with an increased invasion in vitro of colon
cancer cells [85]. Moreover, an elevated Src activity is a
poor prognostic factor in colorectal cancer patients [86].
Hence, it is possible that Src by regulating the u-PA/u-PAR
system may contribute to ECM breakdown, thereby
enabling the access of the detached cancer cells to the
vessels and favoring their intravasation. By degrading
the ECM, motile colon cancer cells create their path to the
vasculature. Moreover, the ability of cancer cells to survive
in the presence of broken ECM fragments constitutes an
inherent property of metastatic cells. Accordingly, selection
for anoikis-resistant cells increases the in vivo metastatic
capacity of melanoma cells in mouse model systems [87].
In the case of colon cancer cells, this might possibly be due
to the fact that they overexpress focal adhesion kinase
(FAK), suggesting that they can by-pass integrin signaling
and thereby survive in the absence of contact with the ECM
[88]. Reciprocally, specific experimental deletion of FAK in
a mouse model of skin tumour is associated with the
induction of cell death and the inhibition of tumour
progression [89]. FAK may contribute to confer survival
by activating survival signal pathways, such as ERK or
AKT [90, 91]. Following their survival and migration in the
degraded ECM, cancer cells gain access to the blood vessel.
At this step, it seems that microvessel diameter is the
dominant parameter underlying colon cancer intravasation
via passive entry [92, 93]. Once again, the cancer cells must
acquire further capacity to survive the process of intra-
vasation. Indeed, a large number of non-metastatic cells
undergo fragmentation when they interact with blood
vessels, whereas metastatic cells demonstrate an increased
survival during this process [94].
As described in the previous sections, colon cancer cells
can also disseminate via the lymphatic vessels, which is
supported by the close correlation existing between liver
metastasis and lymphangiogenesis. The mechanisms by
which lymphangiogenesis contributes to colon cancer and
cancer metastasis in general are still unclear. It is possible
that VEGF-C stimulated lymphatic endothelial cells secrete
chemotactic or mitogenic factors that will attract cancer
cells to the newly growing lymph vessels enabling their
adhesion and intravasation on and through the lymphatic
endothelium [72]. In this context, expression of CXCR4
and CCR7 by human breast cancer cells facilitate their
migration to the lymph nodes [95]. Once they have
interacted with the endothelium of the lymphangiogenic
vessels, the entry of cancer cells in these vessels will be
greatly facilitated by the fact that they are leaky and
tortuous (Fig. 4). As mentioned earlier, colorectal cancer
cells express the CXCR5 chemokine receptor and both
lymph endothelial cells and the liver express its ligand
BCA-1/CXCL13 [79]. It is, then, possible that cancer cells
may be directed via lymphangiogenesis to both lymph
nodes and liver.
Fig. 4 Mechanisms of VEGF-C-induced intravasation of cancer cells
across lymph vessels. In several human cancers, increased expression
of VEGF-C in primary tumours correlates with regional lymph node
metastases. It is possible that a reciprocal cross-talk exists between
tumour cells and lymphatic endothelial cells to induce tumour
lymphangiogenesis and formation of lymph node metastases. Notably,
VEGF-C activates lymphatic endothelial cells (1) that in turn may
secrete chemotactic factors (2). This will contribute to attract cancer
cells bearing appropriate chemokine receptors to the growing lymph
vessels (3), and enable their adhesion and their intra-lymphatic
intravasation
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Circulation of Cancer Cells
As described above, tumour cells enter the blood circulation
directly or indirectly via the lymphatic system. In the case
of colon cancer cells, they use the hepatic–portal circulatory
system to enter the liver. Interestingly, a large number of
cancer cells can be detected in the blood of cancer patients.
However, the number of circulating cancer cells do not
correlate with the level of metastasis. This suggests that
circulation is deleterious for most cancer cells. In fact,
several experimental evidences have shown that, only
0.01% of metastatic clonal cancer cells injected into the
circulation are able to generate metastases. A major
question is then to understand what the fate of cancer cells
that enter the circulation is. This question has been
addressed in reviews by Ann Chambers, Patrick Mehlen
and their colleagues [91, 96]. They report that death of
solitary cells in the circulation occurs mostly through
tumour immune surveillance or destruction by mechanical
stresses. In fact, studies using radio-labeled or fluorescent-
labeled cancer cell lines injected into the circulation and
intravital videomicroscopy support the hypothesis that
solitary cancer cells in the circulation, or soon after
extravasation, are sensitive to apoptosis and die [97–99].
In line with this concept, there is a tenfold decrease in the
number of apoptotic cancer cells that are found at the
secondary site 1 hour following the injection of cells
rendered resistant to apoptosis via overexpression of Bcl2
[98]. As reported above, cancer cell death might occur as a
result of two major mechanisms: cell destruction by
mechanical stress and cell destruction by the immune
system.
The mechanical stress imposed by the circulation is a
major stress that cancer cells must survive to form
metastases. In fact, mechanical destruction of circulating
cancer cells is the first line of defence in the host
microenvironment that acts against hematogenous cancer
dissemination [100]. Cancer cells circulating in the blood
are submitted to strong mechanical forces caused by blood
flow. This is especially important in narrow capillaries and
within the microvasculature of contracting skeletal and
heart muscle, in which sphere-to-cylinder shape transfor-
mation is lethal to most cancer cells [101–103]. Moreover,
NO and ROS are known to trigger apoptosis of cancer cells,
and their production is activated by mechanical forces
including shear and pulsatile stresses and contraction of the
endothelium [91]. The production of these oxyradicals is
required for apoptosis of intravenously injected melanoma
cells or colorectal cancer cells in hepatic sinusoids [104,
105]. Cancer cells have developed several ways to survive
the mechanical stresses associated with circulation. Nota-
bly, they express high levels of stress proteins such as
HSP70. Moreover, they associate with platelets and with
themselves in order to form a shield that protects them
against external aggression [106, 107]. In addition, shear
stress can induce pathways in the cancer cells that involve
activation of integrins leading to adhesion of cancer cells to
endothelial cells, thereby allowing them to escape anoikis.
Nevertheless, these surviving processes are effective to only
a small percentage of circulatory cancer cells since only
0.01% of these form metastases. In summary, the balanced
response of tumour cells to mechanical destruction and
adhesion initiation by circulating stress is an important
mechanism that regulates the spread of hematogenous
cancer.
Immunosurveillance is also involved in detecting and
eliminating circulating tumour cells [108]. Accordingly,
interleukin-2 (IL-2) is effective in treating patients with
metastatic melanoma and kidney cancers, and its anti-
tumoural activity is closely related to its ability to expand
and activate specific subsets of immune cells, such as T
cells and natural killer (NK) cells [109]. Other cytokines,
such as IL-12 and IL-18, stimulate NK cells to suppress
metastasis [110]. Mechanisms of tumour-cell killing by NK
cells seem to be mediated either by the NKG2/perforin or
Trail pathways [111, 112]. Circulating cancer cells have
developed several mechanisms to escape immunosurveil-
lance. In some cases, they can interact with platelets and
fibrinogen to form clots that protect them against immune
cells and facilitate their arrest and their adhesion on the
endothelium [113, 114]. Furthermore, cancer cells may use
inflammation-associated mechanisms to further protect
themselves against apoptosis. For example acute-phase
glycoproteins reach abnormally high levels in patients with
cancer, which correlate with the extent of disease. It has
been shown that these glycoproteins, synthesized by the
liver in response to an inflammatory stimulus, may act as
‘non-specific blocking factors’ protecting tumours against
the host’s immunological attack [115]. Intriguingly, there is
no evidence that human immunodeficiencies are associated
with increased development of metastasis from solid
tumours. Hence, it is still difficult to understand the specific
contribution of tumour-cell death induced by the immune
system in limiting metastasis. Nevertheless, manipulating
the immune system to induce tumour regression still has a
great therapeutic interest.
Extravasation of Cancer Cells
The tumour microenvironment encountered by the invading
cancer cells is a critical component of metastasis and should
be permissive for the metastatic growth of incoming tumour
cells [116]. Notably, the adhesive interactions between the
cancer cells and the endothelial cells of the target organs are
determining components of metastasis. These interactions
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determine the arrest of the circulatory cells in the capillaries
and initiate the cascade of events that culminate in
extravasation or diapedesis of the cancer cells in the
colonized organs. The extravasation of circulating tumour
cells in the host organ requires successive adhesive
interactions between endothelial cells and their ligands or
counter-receptors present on the cancer cells [117]. Typi-
cally, the colon cancer cell/endothelial cell interactions in
the liver imply first a selectin-mediated initial attachment
and rolling of the circulating cancer cells on the endothe-
lium. The rolling cancer cells then become activated by
locally released chemokines present at the surface of
endothelial cells. This triggers the activation of integrins
from the cancer cells allowing their firmer adhesion to
members of the Ig-CAM family such as ICAM and VCAM,
initiating the transendothelial migration and extravasation
processes [118] (Fig. 5). Interestingly, the expression of
endothelial adhesion receptors may be induced by the
cancer cells via a paracrine pathway. This is supported by
studies showing that culture medium supernatants of cancer
cells can trigger the expression of E-selectin on endothelial
cells suggesting that cancer cells may release cytokines
such as TNF-α, IL-β or INF-γ that will directly activate
endothelial cells to express E-selectin and by extension P-
selectin, ICAM-2 or VCAM [119, 120]. On the other hand,
other studies show that cancer cells may initiate the
expression of endothelial adhesion molecules in more
indirect ways. In particular, highly metastatic human
colorectal and mouse lung carcinoma cells, on their entry
into the hepatic microcirculation, initiate a rapid host
inflammatory response by inducing TNF-α production in
resident Kupffer cells. In turn, this event triggers the
expression of E-selectin and VCAM by endothelial cells
and enhances the binding and extravasation of the cancer
cells across sinusoidal endothelial cells [121, 122]. More-
over, the kinetics of the host inflammatory response are
tumour-type specific and rely on interactions with hepatic
Kupffer cells, which supports the concept that the process is
local and liver-specific. In this sense, the process of E-
selectin- and other endothelial adhesion receptor-mediated
metastasis appears to be local. In particular, increased
hepatic local metastasis of B16F1 melanoma cells is
observed following the administration of exogenous IL-
1α, which induces the expression of vascular adhesion
receptor expression, including E-selectin, VCAM-1 and
ICAM-1 enabling cell arrest in terminal portal venules
[123]. Moreover, syngenic colon adenocarcinoma C-26
cells trigger an endogenous inflammatory cascade upon
entry into the liver. The cascade is absent in TNFR1-
deficient mice, which is associated with reduced formation
of liver metastases [124]. Overall, these findings indicate
that, at least in the case of the formation of colorectal
metastases in the liver, the process results from a local
remodeling of the hepatic microenvironment that enables
adhesion and extravasation of the cancer cells. In corollary,
these results further suggest that hepatic remodeling
involving E-selectin-mediated adhesion is an important
component of the hepatic homing of colon cancer metas-
tases.
The binding of cancer cells to E-selectin requires a
molecular scaffold composed of oligosaccharides that are
borne by a carrier protein and possibly a lipid on cancer
cells. This macromolecular scaffolding complex is known
as the selectin counter-receptor and is essential for cell
binding [120]. We previously reported that Death receptor 3
(DR3) is a typical sialylated-a/-x protein that binds E-
selectin and transmits its signal within cancer cells [125].
Other E-selectin ligands expressed by cancer cells involve
ESL-1 and CD44 [107]. Interestingly, the binding of DR3
to E-selectin triggers the reciprocal activation of E-selectin,
which induces a forward signaling in endothelial cells that
contributes to increase endothelial permeability enabling
transendothelial migration of cancer cells [126].
Since the adhesion of colon cancer cells to liver
endothelium requires the presence of endothelial selectins
and their appropriate receptors on the cancer cells, the
degree of expression of selectins on the vascular wall and
the presence of the appropriate ligand on cancer cells are
determinant for their adhesion and extravasation into a
specific organ. Along these lines, the homing of B16F10
melanoma cells to the liver requires the expression of E-
selectin ligands by melanoma cells and the expression of
soluble E-selectin in the liver [127]. On the other hand,
endothelial selectins may be expressed differentially in
Fig. 5 Extravasation of cancer cells is a multi-step process. The first
step consists in the transient adhesion of cancer cells to the
endothelium. It involves endothelial adhesion molecules such as E-
selectin and P-selectin and their counter-receptors present on cancer
cells. This step is associated with the rolling of the cancer cells on the
endothelium (1). The second step consists in a firmer adhesion of
cancer cells to endothelial cells (2). It is mediated through chemo-
attractants and cell adhesion molecules on the endothelium and
integrins on the cancer cells. The third step is characterized by the
extravasation of cancer cells through endothelial cell–cell junctions
(3). EC Endothelial cells, TC tumour cell (adapted from [107])
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blood vessels from different tissues. For example, LPS and
TNFα strongly induce the expression of P-selectin on
endothelial cells of the leptomeninges, but at a weaker level
on some blood vessels of the brain parenchyma [128].
Based on these findings, it can be proposed that the
differential specific interactions of selectins expressed by
endothelial cells of potential target organs and their ligands
expressed on cancer cells are major determinants that
underlie metastasis and organ-specific distribution of
metastases. Along these lines, lung is a secondary meta-
static site for colon cancer and lung endothelial cells also
express E-selectin upon appropriate stimulation [129, 130].
As mentioned previously in this section, it is clear that
adhesion molecules other than E-selectin and its ligands are
also involved in the early adhesion and extravasation of
cancer cells. Notably, direct integrin (α2, α6, β1, β4)-
mediated cell adhesion to the ECM in the space of Disse of
liver sinusoids is required for the successful formation of
liver metastases by colon cancer cells [131]. In addition,
αvβ5 integrin expressed by metastatic colon cancer cells is
required to enable their adhesion to an appropriate counter-
receptor on hepatic microvessels [132]. Moreover, ICAM1
has been shown to dictate the binding of tumour cells to the
pulmonary endothelial cells during metastasis [133].
Colonization
Once circulating cancer cells have gained access to the
secondary site, their subsequent growth will depend on the
compatibility of the cancer cells (seed) with the “soil” that
they encounter in the new organ. Their growth will then be
tightly regulated by molecular interactions between cancer
cells and the new environment. Most cancer cells will die
by apoptosis initiated by an adverse environment [99]. Only
a small subset of them initiate cell division to form
micrometastases, and only a small proportion of these
micrometastases become vascularized and grow to form
macroscopic metastases. In the case of colon cancer cells, it
has been proposed that they release soluble CD44 which
acts as a decoy receptor impairing the interaction of colon
cancer cells with its hyaluronate ligand within the ECM,
thereby conferring resistance to apoptosis [134]. On the
other hand, several lines of evidence indicate that ECM, by
modulating the expression of growth factors and growth-
factor receptors in colon cancer cells, also modulates the
proliferation of these cancer cells in the liver. For example,
hepatocyte-derived ECM, in particular heparin proteogly-
can, stimulate the proliferation of colon cancer cell lines via
induction of autocrine growth factors and their receptors
[135]. Another factor that may limit the proliferation of all
the incoming cancer cells at the secondary site is the fact
that the latter is poorly vascularized at the onset, being
devoid of angiogenesis. This will yield dormant micro-
metastases that may eventually develop in macrometastases
following appropriate remodeling of the microenvironment.
Incidentally, dormant micrometastases that overexpress Ras
will later be more prone to develop metastases that depend
or not on angiogenesis. Moreover, the expression of the
EGF receptor coupled to the expression of growth factors
like TGF-α in the tissue are among the well-known
molecular factors that influence the ability of colon and
other cancer cells to grow in the liver [136, 137].
During the last 10 years, cancer researches have
focussed on the role of chemokines in cancer progression.
Chemokines are chemotactic cytokines that cause the
directed migration of leukocytes along a chemical gradient
leading to the “homing” of leukocytes to specific organs
[138]. These chemokines are induced by inflammatory
cytokines, growth factors and pathogenic stimuli. Immune
cells, endothelial cells and cancer cells express chemokine
receptors and respond to chemokine gradients. Many
cancers have a complex chemokine network that influence
the immune-cell infiltration of the primary and secondary
tumour, as well as tumour cell growth, survival, migration
and angiogenesis [139]. It is now well accepted that
chemokines and their receptors influence the metastatic
potential and site-specific spread of tumour cells [140]. For
example, breast cancer cells and primary breast tumours
express patterns of chemokine receptors that “match”
chemokines specifically expressed in organs to which these
cancers commonly metastasize, namely the lymph nodes,
lung, bone marrow and the liver. Furthermore, blocking one
of the chemokine receptors was found to inhibit metastasis
of breast cancer cells in experimental animal models [95].
Similarly, the chemokine receptor CXCR4 is required
for outgrowth of colon carcinoma micrometastases in the
liver [141].
As described in earlier sections of this review, progres-
sion of solid tumours involves transition of epithelial
transformed cells into mesenchymal cells (EMT), a process
by which cancer cells acquire a more invasive and
metastatic phenotype. Subsequently, the disseminated mes-
enchymal cancer cells must undergo the reverse transition,
MET, at the metastatic site to allow micrometastases to give
rise to a secondary neoplasm corresponding to the primary
one. In this regard, cancer cells from the secondary site re-
express markers of epithelial cells such as E-cadherin [142].
Since initiation of tumour growth at the secondary site is
the rate-limiting step in metastasis, this suggests that the
ability of mesenchymal cells to undergo MET in the
appropriate microenvironments, is a key feature of metas-
tasis [143]. Curiously, despite the importance of MET, little
is known of the mechanisms that are involved. In the case
of colon cancer cell metastasis, it may be speculated that
the liver microenvironment, especially a subpopulation of
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CAFs, is involved in altering the microenvironment that
will contribute to activate the MET process. This will be
achieved by promoting the cross-talk between autocrine/
paracrine growth factors and cell adhesion molecules
expressed by cancer cells and stromal cells. For instance,
CAFs taken from liver of patients having colon metastases
overexpress COX2 and TGF-β2 and they enhance the
proliferation of colon cancer cells in in vitro co-culture
systems [144].]. It is possible that the role of CAFs in
colorectal metastasis is modulated through the production
of IL-8, a chemokine related to invasion and angiogenesis
[145, 146]. In addition, a recent study shows that the kinase
profile of colorectal cells greatly differs whether they are
taken from the primary or the secondary hepatic metastatic
sites, which further indicates that the hepatic microenviron-
ment has remodeled the signaling network of the colon
cancer cells [147].
In summary, the ability of cancer cells to grow in a
specific site depends on features that are inherent to the
cancer cell and to the invaded organ, and on the active
interplay between these factors. Much remains to be learned
about the detailed molecular interactions between cancer
cells and specific secondary site, and probably many organ-
specific growth factor pathways remain to be identified.
However, there is strong evidence indicating that these
interactions are important in determining the survival and
growing potential of a cancer cell in a specific organ.
Concluding Remarks and Clinical Outlook
The journey of colon cancer cells from the primary site to
the secondary sites is paved by obstacles that render the
process destructive and ineffective (Fig. 6). Yet, some cells
succeed and traverse all these impediments to generate
metastases that will become fatal. In each case, the
molecular events that lead to the massive destruction of
the cancer cells or allow their survival during their journey
is governed by an intricate interacting cross-talk between
the cancer cells and its microenvironment. We have briefly
reviewed some of these molecular interactions that charac-
terize the journey of colon cancer cells to the liver. Much
Fig. 6 The journey of a meta-
static cell: from the primary site
to the secondary site. Cancer
cells have a “long and difficult”
journey to go on before colo-
nizing a secondary site and form
metastases. This journey com-
prises several milestones that are
summarized as follows: a Pro-
liferation of primary tumour, b
Local invasion of detached cells.
c Intravasation in a capillary,
and tumour cell survival in
blood circulation: 1, interaction
with leukocytes that may be
destructive or not; 2, aggrega-
tion with platelets, which pro-
tects cancer cells against
mechanical stress and leuko-
cytes; 3, tumour cell–cell aggre-
gation, which protects against
stress and formation of intra
capillary thrombosis. d Arrest
and extravasation in a target
organ. e Metastatic growth in
the new appropriate environ-
ment and formation of a sec-
ondary neoplasm
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remains to be elucidated to fully understand the whole
process. Nevertheless, little by little our knowledge
increases, which contributes to improve our therapeutic
intervention. The discovery that the anti-VEGF monoclonal
antibody bevacuzimab increases the survival of colon
cancer patient by impairing angiogenesis is one the best
example. In fact, any therapy that interferes with the
interaction of cancer cells with its microenvironment has
promising clinical outcome. For example, one may envision
targeting CAFs, EMT or MET as therapeutic purposes.
Targeting the growth of metastases at the secondary site is
particularly attractive since this event occurs often before
the clinical detection of the primary neoplasm. In this
context, components of the TGFβ pathway, a major player
of EMT, are considered to be important new therapeutic
targets. In line with this, new inhibitors of this pathway are
already being tested in pre-clinical and clinical trials.
Notably, four main strategies have been designed for
disrupting TGFβ signaling: inhibition or sequestration of
TGFβ, inhibition of TGFβ receptor kinase activity,
inhibition of SMAD signaling downstream of TGFβ and
restoration of anti-tumour immunity upon TGFβ inhibition
[148]. In this regard, an antisense-based therapy against
TGF-β2 is presently in a phase I/II study investigating
treatment of colorectal cancer [149]. Moreover, approaches
to increase immunosurveillance are under investigation and
should lead to important therapeutic breakthroughs. Ac-
cordingly, interesting results have been obtained in mice
using dendritic cell vaccination [150]. In our opinion, we
believe that the next few years will be more fruitful in
identifying new therapeutic targets in this direction.
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